View in EDS

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.

Saved in:

Bibliographic Details
Title:	Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
Authors:	Cannon CP (AUTHOR), Husted S (AUTHOR), Harrington RA (AUTHOR), Scirica BM (AUTHOR), Emanuelsson H (AUTHOR), Peters G (AUTHOR), Storey RF (AUTHOR), DISPERSE-2 Investigators (CORPORATE AUTHOR)
Source:	Journal of the American College of Cardiology (JACC). Nov2007, Vol. 50 Issue 19, p1844-1851. 8p.
Database:	Academic Search Ultimate

Description
ISSN:	07351097
DOI:	10.1016/j.jacc.2007.07.053